SMILES string
[Cl-].[N+H2](CC(O)c1cc(c(cc1)OC(=O)C(C)(C)C)OC(=O)C(C)(C)C)C
InChI
1S/C19H29NO5.ClH/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6;/h8-10,13,20-21H,11H2,1-7H3;1H
InChI key
VKFAUCPBMAGVRG-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
dipivefrine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Application
Dipivefrine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
Contact dermatitis from dipivefrine with possible cross-reaction to epinephrine.
A Parra et al.
Contact dermatitis, 39(6), 325-326 (1999-01-05)
The effect of topical glaucoma medications evaluated by perimetry.
J-C Lin et al.
The British journal of ophthalmology, 87(6), 792-792 (2003-05-29)
Treatment of progressive normal-tension glaucoma.
E B Werner
Journal of glaucoma, 6(6), 408-411 (1998-01-04)
J Zhao et al.
[Zhonghua yan ke za zhi] Chinese journal of ophthalmology, 36(6), 425-430 (2002-02-21)
Surveying the changes of ocular blood flow by continuous anti-glaucoma eyedrops for one week. Thirty-two patients in glaucoma clinic were divided into three groups, one treated by 0.5% timolol, one by 0.5% levobunolol and the third by 0.1% dipivefrine, twice
An in-service investigation of the additive effect of topical adrenergic agonists and beta-blockers.
W E Gillies et al.
Australian and New Zealand journal of ophthalmology, 26(3), 215-218 (1998-08-26)
We assessed the long-term additive effect of topical adrenaline or adrenaline precursor and beta-blockers because of doubts as to the presence and persistence of such an effect. In 43 patents (20 males and 23 females; mean (+/- SD) age 68.4+/-11.5
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持